Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 25: Beta-Blocker Therapy Post MI in Patients with Preserved LVEF
Author(s): Anna Meta Dyrvig Kristensen Added: 7 months ago
AHA Scientific Sessions 2025 – Dr Anna Meta Dyrvig Kristensen (Copenhagen University Hospital, Bispebjerg and Frederiksberg, DK) presents an individual patient data meta-analysis examining beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction.This comprehensive meta-analysis pooled individual patient data from five randomized controlled… View more

Heart Failure
ESC 25 Hot Line Discussion: VICTOR: Vericiguat in Heart Failure
Author(s): Harriette Van Spall , Faiez Zannad Added: 10 months ago
ESC Congress 2025 - Vericiguat did not reduce the risk of cardiovascular mortality and hospitalization in heart failure with reduced ejection fraction, fewer cardiovascular deaths and all-cause deaths were observed.Host, Dr Harriette Van Spall (McMaster University, CA) is joined on-site at ESC Congress 2025 in Madrid by Dr Faiez Zannad (University of Lorraine, FR) to discuss pivotal results from… View more

Prevention & Chronic Conditions

Heart Failure
THT 2026
Start date: Mar 02, 2026 End date: Mar 04, 2026
OverviewTechnology and Heart Failure Therapeutics (THT) 2026 is a three-day, in-person heart failure conference taking place from 2–4 March 2026 at the Omni Boston Hotel at the Seaport, Boston, MA, United States. The meeting is aimed at interventional cardiologists, heart failure specialists, electrophysiologists, structural heart specialists and the wider heart team managing complex heart… View more

Intervention

Heart Failure
Obesity, Nutrition & Mortality in Acute Heart Failure
Author(s): Mohammed El-Sheikh Added: 1 year ago
In this short interview, Dr Mohammed El-Sheikh discusses the key findings and clinical relevance of his recently published article, “Associations of Obesity and Prognostic Nutritional Index on 1-Year Mortality in Patients with Acute Heart Failure.” View more

Cardiovascular Kidney Metabolic

Heart Failure
John Paisey
Research Area(s) / Expertise:

Atrial Fibrillation

Pacing, Defibrillators & Cardiac Resynchronisation Therapy

 Job title: Consultant Cardiac Electrophysiologist
John Paisey, FRCP, is a Consultant Cardiac Electrophysiologist at University Hospital Southampton. His clinical practice focuses on cardiac rhythm management, complex electrophysiology procedures and device therapy, including subcutaneous ICD implantation. John Paisey is actively involved in advancing contemporary approaches to arrhythmia management and contributes regularly to education and… View more
THT 2025: The SUMMIT Trial
Author(s): Barry Borlaug Added: 1 year ago
THT Conference 2025 - Outcomes assessing the effect of obesity severity on tirzepatide in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) show that patients on tirzepatide with a greater reduction in BMI and baseline waist-to-height ratio had greater improvements in exercise capacity and KCCQ quality of life scores.Dr Barry Borlaug (Mayo Clinic and Foundation,… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Acute Heart Failure: What to Expect in Cardiac Failure Review in 2026
Author(s): Ovidiu Chioncel Added: 1 year ago
In this short video, Dr Ovidiu Chioncel shares why acute heart failure remains a critical area of focus in cardiology, highlighting the urgent need for improved strategies in diagnosis and management.This conversation sets the stage for his upcoming Special Focus in Cardiac Failure Review (Impact Factor: 4.2) in 2026, which will explore this topic further. View more

Heart Failure
Comparison of Haemodynamic Responses to Landiolol Versus Esmolol
Author(s): Georgios Koukoulitsios , Kyriaki Tsikritsaki , Georgios Magklaras , et al Added: 1 year ago

Vascular Disease and Surgery

Heart Failure
Effects of GLP-1 Receptor Agonists in Heart Failure Patients
Author(s): Anastasia Shchendrygina , Amina Rakisheva , Ilya Giverts , et al Added: 1 year ago

Heart Failure
HFSA 25: Excercise Effects of Aficamten Vs Metoprolol in MAPLE-HCM
Author(s): Gregory Lewis Added: 8 months ago
HFSA 25 - Aficamten improves excercise capacity compared to metoprolol in patients with obstructive hypertrophic cardiomyopathy in a prespecified analysis of the MAPLE-HCM study.Dr Gregory Lewis joins us to discuss findings from a prespecified cardiopulmonary exercise testing analysis of the MAPLE-HCM trial, which reveals divergent effects between aficamten and metoprolol on exercise performance… View more

Heart Failure